EchoGo Amyloidosis vs Steth IO
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
EchoGo Amyloidosis is an AI-powered tool designed for the early detection of cardiac amyloidosis by analyzing existing echocardiogram video clips. In contrast, Steth IO is a smartphone-based digital stethoscope that enables real-time auscultation, visualization, recording, and sharing of heart and lung sounds, primarily enhancing telemedicine and remote patient monitoring. While both operate in cardiology, EchoGo focuses on AI-driven diagnosis from imaging data, whereas Steth IO provides a digital solution for physical examination and remote data acquisition.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGo Amyloidosis is an AI-powered screening tool that analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis. In contrast, Steth IO is a smartphone stethoscope that enables healthcare providers to hear, visualize, record, and share heart and lung sounds in real-time, enhancing diagnostic accuracy and facilitating telemedicine and remote patient monitoring.
EchoGo Amyloidosis is designed for seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7, operating as a cloud-based SaaS model. Steth IO operates as a mobile app with a cloud-based system, designed for secure data sharing and can integrate with most existing EMR systems.
EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis based on AI analysis of echocardiographic markers. Steth IO offers real-time visualization of heart and lung sounds (phonocardiogram/spectrogram), the ability to record and save patient exams, and an annotation tool for adding notes.
EchoGo Amyloidosis has a high diagnostic accuracy with 85% sensitivity and 93% specificity for identifying suspected cardiac amyloidosis, performing consistently across CA subtypes. Steth IO is described as enhancing diagnostic accuracy by combining visual and auditory signals, and an AI tool within Steth IO was able to accurately recognize abnormal heart sounds 73% of the time, but specific sensitivity/specificity for the overall device are not detailed.